Edition:
United States

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

2.15USD
11:28am EDT
Change (% chg)

$-0.16 (-6.93%)
Prev Close
$2.31
Open
$2.29
Day's High
$2.30
Day's Low
$2.00
Volume
36,614
Avg. Vol
235,333
52-wk High
$38.00
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Achieve Life Sciences Inc Qtrly Loss Per Share ‍$0.32​
Thursday, 1 Mar 2018 04:30pm EST 

March 1 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE ‍$0.32​.  Full Article

Achieve Announces Prelim Data From Cytisine Phase I/II Clinical Study
Tuesday, 20 Feb 2018 05:30am EST 

Feb 20 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES PRELIMINARY DATA FROM CYTISINE PHASE I/II MULTI-DOSE, PHARMACOKINETIC AND PHARMACODYNAMICS (PK/PD) CLINICAL STUDY.ACHIEVE LIFE SCIENCES INC - CYTISINE WAS WELL-TOLERATED AND REPORTED ADVERSE EVENTS WERE MOSTLY MILD AND SHORT-LIVED IN STUDY.ACHIEVE LIFE SCIENCES - SUBJECTS WHO DID NOT ACHIEVE ABSTINENCE HAD "SIGNIFICANT REDUCTION" IN NUMBER OF DAILY CIGARETTES SMOKED BY END OF TREATMENT.ACHIEVE LIFE SCIENCES INC - NO ADVERSE EVENTS WERE SEVERE, SERIOUS, OR LED TO WITHDRAWAL FROM STUDY.ACHIEVE LIFE SCIENCES INC - EXPECTS TO INITIATE CYTISINE PHASE 3 DEVELOPMENT PROGRAM IN MID-2018 REQUIRED FOR FDA APPROVAL OF CYTISINE IN U.S..  Full Article

Achieve qtrly loss per share $0.90‍​
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article

Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD
Thursday, 26 Oct 2017 05:30am EDT 

Oct 26 (Reuters) - Sopharma Ad <3JR.BB>:Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​.Achieve Life Sciences Inc - ‍exclusive license agreement provides supply of Cytisine to co for up to 20 years​.Achieve Life Sciences Inc - ‍sopharma agrees to produce CGMP-grade Cytisine for achieve's use in development and commercialization of Cytisine​.  Full Article

Achieve announces share purchase agreement with Lincoln Park Capital Fund
Thursday, 14 Sep 2017 04:06pm EDT 

Sept 14 (Reuters) - Achieve Life Sciences Inc :Achieve announces share purchase agreement with Lincoln Park Capital Fund LLC.Achieve Life Sciences - ‍Entered share purchase agreement with Lincoln Park Capital Fund pursuant to which achieve may sell up to $11.0 million of shares.Achieve Life Sciences - Intends to use net proceeds it receives from offering to advance clinical development of Cytisine, among others​.  Full Article

FDA accepts Achieve's IND for its smoking cessation drug
Thursday, 10 Aug 2017 04:30pm EDT 

Aug 10 (Reuters) - Achieve Life Sciences Inc -:Achieve announces FDA acceptance of the investigational new drug application (IND) for cytisine as a smoking cessation treatment.Achieve Life Sciences Inc- ‍achieve expects to commence a phase 3 trial of cytisine in united states in first-half of 2018​.  Full Article

Oncogenex Pharmaceuticals reports Q1 loss per share $0.11
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Oncogenex Pharmaceuticals Inc :Oncogenex Pharmaceuticals Inc. reports financial results for first quarter 2017.Oncogenex Pharmaceuticals Inc says revenue for three months ended March 31, 2017 decreased to zero from $2.9 million for three months ended march 31, 2016.Oncogenex Pharmaceuticals Inc - qtrly loss per share $0.11.  Full Article

Oncogenex Pharma and Achieve Life Science announce strategic collaboration with National Institutes of Health
Wednesday, 1 Mar 2017 09:00am EST 

Oncogenex Pharmaceuticals Inc : Oncogenex Pharma says Achieve Life Science and co announce strategic collaboration with National Institutes of Health to advance development of cytisine . Oncogenex Pharmaceuticals Inc says results of initial study are expected in second-quarter of 2017 .Oncogenex Pharmaceuticals Inc says multiple key cytisine development and regulatory milestones expected in 2017.  Full Article

Oncogenex Pharma believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for next 12 months
Thursday, 23 Feb 2017 09:00am EST 

Oncogenex Pharmaceuticals Inc : Oncogenex pharma - believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for at least next 12 months . Oncogenex pharmaceuticals inc - revenue for q4 was zero .Oncogenex pharmaceuticals inc - net loss for q4 and year ended december 31, 2016 was $5.8 million and $20.1 million, respectively.  Full Article

Oncogenex Pharmaceuticals says clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated
Tuesday, 21 Feb 2017 09:00am EST 

Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals, Inc. announces phase 2 apatorsen data for two clinical trials presented at the American Society Of Clinical Oncology (asco) 2017 genitourinary cancers symposium .Oncogenex Pharmaceuticals Inc- clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated.  Full Article

BRIEF-Achieve Qtrly Basic And Diluted Net Loss Per Share $0.24

* QTRLY BASIC AND DILUTED NET LOSS PER SHARE $0.24 Source text for Eikon: Further company coverage: